Just a couple of days after Valeant board member Bill Ackman touted the company’s R&D program as an industry leader, it’s run into a snag.

Takeda is finally on the up-and-up after posting growth in its last fiscal year. And to help keep that growth coming, it’s exploring an asset sale to drum up…

The $250 million gender bias suit against Merck & Co. just picked up more steam.

Sales of Roche’s cancer drugs remain strong, giving the Swiss drugmaker a solid push in the first half of the year. And while execs acknowledge that a swarm of…

Biogen CEO George Scangos is going out on an up note. The biotech, which today reported street-beating Q2 results, said he is stepping down as soon as a…

AstraZeneca’s ZS-9 setback last month did Relypsa a favor: It handed Veltassa sole control of the hyperkalemia market. That didn't hurt Relypsa’s chances…

Gilead may have won the patent manipulation suit thrown its way earlier this year by the AIDS Healthcare Foundation. But outrage over its pricing practices and…

With both U.S. presidential candidates promising action on drug prices, November’s election could trigger a sea change in the industry, Novartis CEO Joe…

Merck’s Keytruda may have found itself an unexpected ambassador. Rikki Rockett, drummer for the rock band Poison, announced that his oral cancer is gone after…